Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Announces Target Price $110
Morgan Stanley Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Boston Scientific Analyst Ratings
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $110
Goldman Sachs Raises Price Target on Boston Scientific to $103 From $102, Maintains Buy Rating
Boston Scientific Is Maintained at Buy by TD Cowen
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $110
TD Cowen Adjusts Price Target on Boston Scientific to $110 From $100, Maintains Buy Rating
Boston Scientific Is Maintained at Overweight by Wells Fargo
Boston Scientific Analyst Ratings
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $100
Citi Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $107
CICC Initiates Boston Scientific at Outperform With $116 Price Target
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $98
Boston Scientific's Promising Clinical Trials and Innovative Approaches Justify Buy Rating
Boston Scientific Is Maintained at Buy by Canaccord Genuity
Boston Scientific Analyst Ratings
CCORF Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $101
Piper Sandler Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $95
Piper Sandler Sticks to Their Buy Rating for Boston Scientific (BSX)